Apr 5, 2018
Aratana confirmed it received a notice of nomination of three director candidates for election to the Company's Board of Directors from Engaged Capital, LLC and certain of its affiliated entities.
Mar 13, 2018
Aratana announced its fourth quarter and full year 2017 financial results, reporting total net revenues of $10.4 million and a net loss of $15.6 million or $0.37 diluted loss per share.
Mar 2, 2018
The Company plans on attending Cowen and Barclays investment conferences.
Mar 1, 2018
Aratana announced it licensed exclusive, worldwide rights to develop and commercialize AT-019 from AskAt Inc. AT-019 is a potent and innovative EP4 receptor antagonist with potential in pain, inflammation and other indications.
Feb 13, 2018
Aratana will host a live conference call on Wednesday, March 14, 2018 at 8:30 a.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2017.
Jan 18, 2018
Aratana announced GALLIPRANT® (grapiprant tablets) was named Animal Pharm's Best Companion Animal Product for 2017.
Jan 11, 2018
Together with Elanco, Aratana announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
Dec 20, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced the...
Dec 15, 2017
Aratana Therapeutics, Inc. (NASDAQ: PETX) has received top-line pivotal field effectiveness study results for AT-016, an investigational adipose-derived allogeneic stem cell therapeutic candidate...
Nov 28, 2017
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats, today announced that it has...